The Bcl-2 family of proteins plays an important role in the intrinsic pathway of cell apoptosis. Overexpression of prosurvival
members of this family of proteins is often associated with the development of many types of cancer and confers resistance
against conventional therapeutic treatments. Accordingly, antagonism of its protective function has emerged as an encouraging
anticancer strategy. In the present work, we use a pharmacophore for describing interaction between the BH3 domain of different pro-apoptotic members and the pro-survival protein Bcl-xL in order to identify new lead compounds. In the strategy followed in the present work, the harmacophore was derived from molecular
dynamics studies of different Bcl-xL/BH3 complexes. This pharmacophore was later used as query for 3D database screening. Hits
obtained from the search were computationally assessed, and a subset proposed for in vitro testing. Two of the 15 compounds assayed were found able to disrupt the Bcl-xL/Bak(BH3) complex with IC50 values in the lower micromolar range. Finally, docking studies were performed to explore the binding mode of these compounds to Bcl-xL for further modifications.
CitationPinto, M. [et al.]. Rational design of new class of BH3-mimetics as inhibitors of the Bcl-X(L) protein. "Journal of chemical information and modeling", Juny 2011, vol. 51, núm. 6, p. 1249-1258.
Tots els drets reservats. Aquesta obra està protegida pels drets de propietat intel·lectual i industrial corresponents. Sense perjudici de les exempcions legals existents, queda prohibida la seva reproducció, distribució, comunicació pública o transformació sense l'autorització del titular dels drets.
Per a qualsevol ús que se'n vulgui fer no previst a la llei, dirigiu-vos a: firstname.lastname@example.org